Literature DB >> 34342009

Sociodemographic and clinical factors associated with transdermal alcohol concentration from the SCRAM biosensor among persons living with and without HIV.

Veronica L Richards1, Yiyang Liu1, Jessica Orr2, Robert F Leeman3,4, Nancy P Barnett5, Kendall Bryant6, Robert L Cook1, Yan Wang1.   

Abstract

BACKGROUND: Transdermal alcohol biosensors can objectively monitor alcohol use by measuring transdermal alcohol concentration (TAC). However, it is unclear how sociodemographic and clinical factors that influence alcohol metabolism are associated with TAC. The main aim of this study was to examine how sociodemographic factors (sex, age, race/ethnicity) and clinical factors (body mass index, liver enzymes: alanine aminotransferase [ALT] and aspartate transaminase [AST]), alcohol use disorder, and HIV status were associated with TAC while controlling for level of alcohol use.
METHODS: We analyzed data from a prospective study involving contingency management for alcohol cessation among persons living with and without human immunodeficiency virus (HIV) that used the Secure Continuous Remote Alcohol Monitoring (SCRAM) biosensor. Forty-three participants (Mage  = 56.6 years; 63% male; 58% people living with HIV) yielded 183 SCRAM-detected drinking days. Two indices derived from SCRAM: peak TAC (reflecting level of intoxication) and TAC area under the curve (TAC-AUC; reflecting alcohol volume)-were the main outcomes. Self-reported alcohol use (drinks/drinking day) measured by Timeline Followback was the main predictor. To examine whether factors of interest were associated with TAC, we used individual generalized estimating equations (GEE), followed by a multivariate GEE model to include all significant predictors to examine their associations with TAC beyond the effect of self-reported alcohol use.
RESULTS: Number of drinks per drinking day (B = 0.29, p < 0.01) and elevated AST (B = 0.50, p = 0.01) were significant predictors of peak TAC. Positive HIV status, female sex, elevated AST, and number of drinks per drinking day were positively associated with TAC-AUC at the bivariate level, whereas only self-reported alcohol use (B = 0.85, p < 0.0001) and female sex (B = 0.67, p < 0.05) were significant predictors of TAC-AUC at the multivariate level.
CONCLUSIONS: HIV status was not independently associated with TAC. Future studies should consider the sex and liver function of the participant when using alcohol biosensors to measure alcohol use.
© 2021 Research Society on Alcoholism.

Entities:  

Keywords:  HIV; SCRAM; biosensor; heavy drinking; transdermal alcohol concentration

Mesh:

Substances:

Year:  2021        PMID: 34342009      PMCID: PMC8526382          DOI: 10.1111/acer.14665

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.928


  34 in total

1.  Phosphatidylethanol Detects Moderate-to-Heavy Alcohol Use in Liver Transplant Recipients.

Authors:  Michael Francis Fleming; Matthew J Smith; Erika Oslakovic; Michael R Lucey; Jenny X Vue; Patrice Al-Saden; Josh Levitsky
Journal:  Alcohol Clin Exp Res       Date:  2017-03-20       Impact factor: 3.455

2.  Experiences with SCRAMx alcohol monitoring technology in 100 alcohol treatment outpatients.

Authors:  Sheila M Alessi; Nancy P Barnett; Nancy M Petry
Journal:  Drug Alcohol Depend       Date:  2017-06-28       Impact factor: 4.492

3.  Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease.

Authors:  Scott H Stewart; David G Koch; Ira R Willner; Raymond F Anton; Adrian Reuben
Journal:  Alcohol Clin Exp Res       Date:  2014-05-21       Impact factor: 3.455

4.  Transdermal alcohol concentration data collected during a contingency management program to reduce at-risk drinking.

Authors:  Donald M Dougherty; Tara E Karns; Jillian Mullen; Yuanyuan Liang; Sarah L Lake; John D Roache; Nathalie Hill-Kapturczak
Journal:  Drug Alcohol Depend       Date:  2014-12-31       Impact factor: 4.492

5.  A preliminary randomized controlled trial of contingency management for alcohol use reduction using a transdermal alcohol sensor.

Authors:  Nancy P Barnett; Mark A Celio; Jennifer W Tidey; James G Murphy; Suzanne M Colby; Robert M Swift
Journal:  Addiction       Date:  2017-02-22       Impact factor: 6.526

6.  Alcohol biomarkers in applied settings: recent advances and future research opportunities.

Authors:  Raye Z Litten; Ann M Bradley; Howard B Moss
Journal:  Alcohol Clin Exp Res       Date:  2010-04-05       Impact factor: 3.455

Review 7.  Age, alcohol metabolism and liver disease.

Authors:  Patrick Meier; Helmut K Seitz
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2008-01       Impact factor: 4.294

8.  The Potential Clinical Utility of Transdermal Alcohol Monitoring Data to Estimate the Number of Alcoholic Drinks Consumed.

Authors:  Donald M Dougherty; Nathalie Hill-Kapturczak; Yuanyuan Liang; Tara E Karns; Sarah L Lake; Sharon E Cates; John D Roache
Journal:  Addict Disord Their Treat       Date:  2015-09

Review 9.  Alcohol Use Disorder in the Age of Technology: A Review of Wearable Biosensors in Alcohol Use Disorder Treatment.

Authors:  Rachel E Davis-Martin; Sheila M Alessi; Edwin D Boudreaux
Journal:  Front Psychiatry       Date:  2021-03-22       Impact factor: 4.157

Review 10.  Biomonitoring for Improving Alcohol Consumption Surveys: The New Gold Standard?

Authors:  Thomas K Greenfield; Jason Bond; William C Kerr
Journal:  Alcohol Res       Date:  2014
View more
  1 in total

1.  Examining features of transdermal alcohol biosensor readings: A promising approach with implications for research and intervention.

Authors:  Daniel J Fridberg; Yan Wang; Eric Porges
Journal:  Alcohol Clin Exp Res       Date:  2022-02-27       Impact factor: 3.928

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.